Description: Biomerieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company's diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France.
Home Page: www.biomerieux.com
376 Chemin De l’Orme
Marcy l'Étoile,
69280
France
Phone:
33 4 78 87 20 00
Officers
| Name | Title |
|---|---|
| Mr. Alexandre Merieux | Chairman & CEO |
| Mr. Pierre Boulud | Chief Operating Officer of Clinical Operations |
| Mr. Frederic Beseme | Head of CSR |
| Mr. Guillaume Bouhours | Exec. VP of Purchasing and Information Systems & CFO |
| Sylvain Morgeau | Investor Relations |
| Ms. Valerie Leylde | Exec. VP of HR, Communications & CSR |
| Mr. François Lacoste | Exec. VP of R&D |
| Mr. Mark Miller | Exec. VP of Medical Affairs |
| Mr. Pierre Charbonnier | Exec. VP of Quality, Manufacturing & Supply Chain |
| Mr. Yasha Mitrotti | Exec. VP of Industrial Microbiology |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 25 |
|---|---|
| Trailing PE: | 20.9028 |
| Price-to-Book MRQ: | 3.1842 |
| Price-to-Sales TTM: | 3.6325 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12084 |